Sponsored by
This is an exciting combination of treatments. MB-101 is a CAR-T cell therapy and MB-108 is an oncolytic virus. The combination is named MB-109. Each component alone had shown safety as well as activity but not really enough to get approval on their own. The combination makes sense and together they may make a major breakthrough. I will be watching this one closely.